Role of PD-L1 assessment in advanced NSCLC: does it still matter?
Alessandro Rizzo1, Filippo Gustavo Dall'Olio1, Annalisa Altimari2
1Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni.
Anti-Cancer Drugs
|July 7, 2021
Abstract
No abstract available in PubMed .
More Related Videos
07:43Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
10.7K
07:42Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
5.3K
